Attovia Raises $289 Million in Biotech IPO

Attovia Therapeutics has successfully completed an initial public offering that raised two hundred and eighty-nine million dollars to finance its pipeline of treatments for skin disorders and inflammatory conditions. This transaction marks the twelfth drug company this year to secure at least one-fifth billion dollars from a listing, nearly matching the high totals observed during the pandemic peak according to industry data.

The startup sold seventeen million shares at seventeen dollars each in an upsized deal that secured forty-five per cent more capital than originally anticipated. This funding values Attovia at seven hundred and sixty-seven million dollars with trading expected on the Nasdaq under the ticker symbol ATTO. The company launched as a spinout of Alamar Biosciences in 2023 to develop antibody drugs utilising its proprietary technology designed for hard-to-reach biological targets.

Prior to this public listing, Attovia raised approximately two hundred and fifty-six million dollars through venture funding. This capital advanced an experimental drug known as ATTO-1310 which is currently in Phase 1 testing alongside a portfolio of five other preclinical prospects targeting various inflammatory or respiratory conditions. The primary candidate targets IL-31 referred to by the company as the itch cytokine and is being evaluated for chronic pruritis and high-itch eczema.

Further studies are planned against itching associated with chronic kidney and liver diseases while regulatory filings indicate a path for patients with elevated levels of this specific target. Two other drug candidates are close to human testing including ATTO-2306 which targets both IL-31 and another cytokine known as IL-13.

This second candidate is viewed as a possible treatment for inflammatory skin conditions like eczema or chronic spontaneous urticarias. The third prospect named ATTO-1091 acts on multiple fronts to treat inflammatory bowel disease by targeting TL1A, a protein currently being studied by several major pharmaceutical companies including Merck and Roche.

Attovia’s offering ranks ninth in total proceeds for the year which has seen multiple price record-breaking deals. The sector has already surpassed the low eleven IPO totals recorded previously while four more drugmakers could price offerings over the next two days. Young biotechs usually get acquired instead of profitably selling their own medicines but a growing number are proving they can succeed independently.

This shift makes the sector more broadly appealing to investors as some say it demonstrates viability beyond acquisition strategies. Striking study results indicated that a new type of medicine may improve on existing immunotherapy spurring a wave of research practically overnight.